{"i": ["SP", "Dapsone", "anti - retroviral therapy ( ART )", "pyrimethamine .", "sulphadoxine", "intravenous quinine , chloramphenicol and penicillin .", "AL", "capped pill bottles", "sulphonamide or dapsone", "sodium hydroxide", "acetonitrile : triethylamine", "DDS .", "paracetamol", "CPD", "AL and chlorproguanil - dapsone ( CPD , LapdapTM )", "sulphadoxine - pyrimethamine ( SP ) to artemether - lumefantrine ( AL , CoartemTM ),", "standard ( pyrimethamine", "anti - retroviral therapy", "artemether - lumefantrine ( AL ) and chlorproguanil - dapsone ( CPD ),", "AL and CPD", "anti - folate combination", "Sulphadoxine - pyrimethamine ( SP )", "Lumefantrine", "AL , CPD", "artemisinin - combination therapy", "AL and CPD treatment", "artemether - lumefantrine , chlorproguanil - dapsone or sulphadoxine - pyrimethamine", "dichloromethane", "Dapsone ( DDS )", "artemether ( AM ) with lumefantrine ( LU ).", "CPD and AL", "lorazepam", "chlorproguanil - dapsone - artesunate", "chlorproguanil - dapsone ( CPD ), artemether - lumefantrine ( AL ) and sulphadoxine - pyrimethamine ( SP ) CPD", "MEMSTM", "parenteral quinine", "dapsone", "CPG"], "o": ["death or admission to hospital", "serious adverse events", "LU concentration", "- 7 plasma dapsone or lumefantrine concentrations", "DDS concentration", "LU levels", "ACPR", "SAE rates", "packed cell volume ( PCV", "features of severe malaria ( convulsions and fever with a positive blood slide", "recrudescence", "adherence , day - 7 plasma drug concentrations and clinical responses", "Convulsions", "drug questionnaires , pill counting , assessment of pharmacy repeated prescriptions , MEMSTM and drug level monitoring", "Hb", "concentrations of dapsone ( DDS ) and lumefantrine ( LU )", "lumefantrine levels", "vomiting and abdominal pain", "mean Hb level", "day - 7 dapsone or lumefantrine concentrations", "treatment failure", "ACPR outcome", "day - 7 LU concentrations", "serious adverse events ( SAEs ) and Hb changes", "hospital admission with features of severe malaria", "LU", "day - 14 efficacy", "DDS concentrations", "ACPR rate", "recruitment parasite count", "Median day - 7 dapsone concentrations", "PCV", "Self - reported adherence", "median ( IQR ) day - 7 LU concentration", "LU concentrations", "PP day - 28 ACPR rate", "negative blood slides", "convulsion and further fevers", "normal blood glucose concentration .", "adherence levels", "height", "mean day - 3 LU concentrations", "palpable spleen .", "day - 28 ACPR", "positive malaria blood slide , PCV", "median day - 7 LU concentration", "\" adequate clinical and parasitological response \" ( ACPR ) rates .", "jaundiced", "LLOQ", "changes in Haemoglobin [ Hb ]", "median day - 7 DDS concentration", "patient adherence", "Parasite count", "ACPR rates", "dose", "cure rate", "plasma LU levels", "features of severe malaria", "lower limit of quantification ( LLOQ )", "adherence rate", "blood transfusion", "adequate clinical and parasitological response ( ACPR ) rates", "lumefantrine concentration", "severe anaemia", "median ( IQR ) LU concentrations", "adherence", "CPD efficacy", "median day - 7 DDS concentrations", "Adherence", "admission to hospital for blood transfusion .", "SAEs", "haemoglobin concentration [ Hb", "PP day - 28 and day - 42 ACPR rates", "adherence rates"]}